{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-035762","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2026-08-03T13:35:12+00:00","discovered_at":"2026-08-03T13:36:00.339634+00:00","generated_at":"2026-08-03T13:36:07.626038+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Lipocine appoints Michael Grissinger to board of directors","bullets":["Grissinger appointed as independent director effective August 3, 2026.","Receives initial option grant of 2,000 shares and annual retainer of $55,000.","Over 20 years at Johnson & Johnson in licensing and corporate development roles.","Currently serves on boards of Aprea Therapeutics (APRE) and Adicet Bio (ACET).","Chairman cites his dealmaking experience to advance pipeline and partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-035762","json":"https://secwatch.observer/filing/0001493152-26-035762.json","markdown":"https://secwatch.observer/filing/0001493152-26-035762.md","text":"https://secwatch.observer/filing/0001493152-26-035762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226035762/0001493152-26-035762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226035762/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T13:36:07.626038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9f8517cc0","claim":"Michael Grissinger was appointed as director at Lipocine Inc..","evidence_excerpt":"On August 3, 2026, the Board of Directors of the Company expanded the Board of Directors to five members and appointed Michael Grissinger as a director, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226035762/0001493152-26-035762-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}